Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:30 PM ET 10-K
Financial Results Twist Bioscience Corp TWST

Twist Bioscience FY 2026 Results: Net Loss of $130M, Loss Widens

Twist Bioscience reported net proceeds of approximately $327.7 million from an August 2026 public offering and $97.1 million from an at-the-market program. Despite these capital raises, the company anticipates continued net losses and negative free cash flows for the near future while expanding international operations, which accounted for 41% of revenue in fiscal 2026.

Key figure
Net loss $130M
4:30 PM ET 8-K
Capital Raise Keurig Dr Pepper Inc. KDP

Keurig Dr Pepper Capital Raise of $2.3B

Keurig Dr Pepper completed a public offering of 66,666,667 shares of common stock (including the full exercise of the underwriters' option) at a price of $34.50 per share. The company received approximately $2.25 billion in net proceeds, which it intends to use to repay outstanding debt and accelerate deleveraging. This financial move is intended to optimize the balance sheet ahead of the company's planned separation into two independent public companies in early 2027.

Value
$2.3B
Counterparty
Goldman Sachs & Co. LLC
4:30 PM ET 8-K
Loan & Debt American Tower Corp AMT

American Tower $1.33B Debt Financing with Morgan Stanley & Co. International plc

American Tower Corporation priced a registered public offering of senior unsecured notes in two tranches: €600 million due 2031 at 4.200% and €600 million due 2034 at 4.500%. The total aggregate principal amount is approximately $1.33 billion USD, with net proceeds intended for general corporate purposes and refinancing upcoming euro-denominated debt maturities.

Value
$1.33B
Counterparty
Morgan Stanley & Co. International plc
4:30 PM ET 8-K
Stock Buyback Patrick Industries Inc PATK

Patrick Industries Announces $200M Stock Buyback

Patrick Industries announced that its Board of Directors authorized a replenishment of its share repurchase program to $200 million and increased its quarterly cash dividend by 11% to $0.52 per share. While the buyback was authorized, the company noted it is currently restricted from repurchasing shares due to operating covenants in its pending all-stock merger agreement with LCI Industries.

Value
$200M
Term
24 months
4:30 PM ET 8-K
Investor Presentation Harrow, Inc. HROW

Harrow Investor Presentation

Harrow, Inc. filed a formal corporate presentation to be used by management at the Jefferies Global Healthcare Conference in London. The presentation highlights the company's ophthalmic pharmaceutical portfolio, including core growth brands VEVYE, IHEEZO, and TRIESENCE. The filing is a standard Regulation FD disclosure to provide the investment community with updated strategic and commercial information.

4:30 PM ET 8-K
Financial Results T Stamp Inc IDAI

T Stamp Financial Results

T Stamp Inc. (Trust Stamp) reported financial results for the nine months ended September 30, 2026, featuring a 28% increase in net revenue to $2.85 million. The company noted that revenue growth is significantly outpacing the growth in cash expenses, driven by work with an S&P 500 bank and a multinational telecommunications corporation. Trust Stamp also highlighted a maturing revenue pipeline with a conservative FY 2027 projection of $8.17 million in booked revenue.

Term
9 months
4:29 PM ET 8-K
M&A Deal Pool Corp POOL

Pool M&A Deal with Team Horner Group, Inc.

Pool Corporation (POOL) has signed a definitive agreement to acquire Team Horner Group, Inc., a Florida-based wholesale distributor of swimming pool products. The acquisition includes 18 sales centers and manufacturing operations for pool heat pumps and salt chlorine generators. The deal is expected to close in Q1 2027 and will be funded through POOL's revolving credit facility and cash on hand.

Counterparty
Team Horner Group, Inc.
4:29 PM ET 8-K
Financial Results Vulcan Infrastructure & Power Inc. VIP

Vulcan Infrastructure & Power Financial Results

Vulcan Infrastructure and Power reported Q3 2026 financial results, highlighting a strategic transition toward AI and high-performance computing (HPC) infrastructure. The company strengthened its balance sheet by completing a $39.3 million strategic investment and redeeming its 2026 Senior Notes, effectively eliminating its 2026 debt maturity.

“During the third quarter and subsequent to quarter-end, we completed three important steps in Vulcan’s transition. In September, we closed a $39.3 million strategic investment from Atlas Holdings, Machine Investment Group, Conversant Capital, and other investors, and in October we completed the full redemption of our 8.50% Senior Notes due 2026 (the “2026 Notes”).”

Jordan Kovler, CEO

“Our immediate focus is on advancing our owned sites at Dresden and Columbus through predevelopment work and with AI/HPC customers. Our objective is to translate the power and infrastructure value of these assets into contracted, predictable, long-duration cash flows.”

Jordan Kovler, CEO
4:29 PM ET 8-K
Financial Results Oric Pharmaceuticals, Inc. ORIC

Oric Pharmaceuticals Financial Results

ORIC Pharmaceuticals reported third quarter 2026 financial results and provided updates on its late-stage oncology portfolio, including the initiation of the Himalayas-1 Phase 3 trial for rinzimetostat in prostate cancer. The company ended the quarter with $345 million in cash and investments, which is expected to fund operations into the second half of 2028.

“Recent clinical data updates reinforce our confidence in the best-in-class potential of our late-stage portfolio, with rinzimetostat continuing to demonstrate an efficacy and safety profile in prostate cancer that is differentiated from current standards of care and the only other PRC2 inhibitor in Phase 3 development, and with enozertinib setting a new benchmark in 1L EGFR atypical NSCLC.”

Jacob M. Chacko, M.D., president and chief executive officer

“With the first Phase 3 trials either underway or planned across both programs and supported by a strong balance sheet, we are laser focused on execution in pursuit of our mission to Overcome Resistance In Cancer.”

Jacob M. Chacko, M.D., president and chief executive officer
4:29 PM ET 8-K
Financial Results Enanta Pharmaceuticals Inc ENTA

Enanta Pharmaceuticals Financial Results

Enanta Pharmaceuticals reported fiscal fourth quarter 2026 revenue of $12.9 million and a net loss of $28.3 million, driven by royalty revenue from AbbVie's HCV regimen. The company highlighted clinical progress in its RSV and immunology pipelines, including the completion of enrollment for its Phase 2b LOTUS trial. Enanta also announced the planned retirement of CEO Jay R. Luly by February 2027.

Counterparty
AbbVie

“During fiscal 2026 we made significant progress across our virology and immunology portfolios. In RSV, we completed enrollment in LOTUS, a Phase 2b trial of zelicapavir in pediatric patients, with topline data expected in the first quarter of 2027. We also began dosing patients in RESOLVE, a Phase 2b/3 trial of zelicapavir in adults at high risk of severe disease and anticipate reporting data from the Phase 2b portion in 2027.”

Jay R. Luly, Ph.D., President and Chief Executive Officer

“In parallel, we are advancing a growing immunology portfolio focused on developing best-in-class oral medicines that have the potential to raise the standard of care across multiple immune-mediated diseases. We expect to complete dosing in the EDP-978 Phase 1 trial by year-end 2026 and now plan to report data in the first quarter of 2027.”

Jay R. Luly, Ph.D., President and Chief Executive Officer
4:29 PM ET 8-K
Financial Results Omeros Corp OMER

Omeros Financial Results

Omeros Corporation reported Q3 2026 financial results, highlighted by a 26% sequential increase in net revenue for YARTEMLEA to $35.9 million. The company reported a GAAP net loss of $57.4 million, primarily driven by a $62.0 million non-cash mark-to-market adjustment on convertible notes, while achieving positive operating cash flow of $13.3 million.

Term
Q3 2026

“YARTEMLEA sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow. As expected, 340B participation increased, reflecting substantial expansion of our customer base and increased outpatient use of YARTEMLEA. That momentum has continued into the fourth quarter, with YARTEMLEA revenues continuing to grow.”

Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer
4:29 PM ET 8-K
Financial Results Lifeloc Technologies, Inc LCTC

Lifeloc Technologies Financial Results

Lifeloc Technologies reported Q3 2026 net revenue of $2.522 million, a 12% increase year-over-year, and a narrowed net loss of $85 thousand. The company highlighted margin improvements from price increases and continued heavy R&D investment in its SpinDetect drug analyzer platform, which is entering beta testing.

Term
Q3 2026
4:29 PM ET 8-K
Financial Results Getty Images Holdings, Inc. GETYQ

Getty Images Holdings Financial Results

Getty Images reported Q3 2026 revenue of $234.0 million, a 2.5% year-over-year decrease, and a net loss of $564.5 million primarily driven by $563.2 million in non-cash impairment charges. The company also announced it has initiated a prepackaged Chapter 11 restructuring process to transition to a privately held company with the support of the Getty family and Koch Equity Development.

Term
Q3 2026

“As recently announced, we initiated a financial restructuring to significantly strengthen our financial foundation and accelerate our ability to invest for growth with the support of the Getty family, Koch Equity Development and our lenders as a privately held company.”

Craig Peters, Chief Executive Officer of Getty Images

“We continue to service our customers through the world's best authentic visual content and coverage. Importantly, we remain focused on what we do best, which is helping our customers engage their audiences.”

Craig Peters, Chief Executive Officer of Getty Images
4:29 PM ET 8-K
Leadership Change Carpenter Technology Corp CRS

Carpenter Technology Leadership Change

Carpenter Technology Corporation promoted Marshall D. Akins to Senior Vice President – Chief Operating Officer, effective immediately. The company also announced the promotions of John Huyette to Vice President – Chief Commercial Officer and Bill Besash to Vice President – Investor Relations and Corporate Development. Mr. Akins will receive a base salary of $580,000 and an annual equity incentive award valued at $1.3 million.

4:29 PM ET 8-K
Financial Results Luvu Brands, Inc. LUVU

Luvu Brands Financial Results

Luvu Brands reported first quarter fiscal 2027 net sales growth of 10% to $6.8 million, driven by strength in wholesale and international channels. Despite the revenue growth, the company reported a net loss of $365,000 as higher freight and manufacturing labor costs compressed gross margins to 26.2%.

Term
Q1 2027

“We opened fiscal 2027 with double-digit top-line growth, led by continued strength in our Wholesale channel, particularly adult retailers and international customers, and by better conversion on our Liberator website following its move to the Shopify platform. We are adding distribution points at home and abroad, and we are encouraged by the momentum in both our Direct and Wholesale channels.”

Louis Friedman, Founder, Chief Executive Officer of Luvu Brands
4:29 PM ET 8-K
Financial Results Roadzen Inc. RDZN

Roadzen Financial Results

Roadzen reported record quarterly revenue of $17.6 million for Q2 fiscal 2027, representing 28.6% year-over-year growth. The company achieved its first-ever positive Adjusted EBITDA quarter and narrowed its operating loss by 24% as it targets a $100 million annualized revenue run rate by fiscal year-end.

Term
Q2 2027

“This is the quarter we have been building toward for two years. Roadzen generated positive Adjusted EBITDA for the first time in its history, on record revenue of $17.6 million, our third record quarter in a row, after nine consecutive quarters of disciplined improvement.”

Rohan Malhotra, Founder and CEO of Roadzen

“We process more than three million claims a year, our driver-safety AI runs across billions of miles of real-world driving, and our AI agents now do work inside inspection, claims and repair that used to take weeks, and that is the engine behind these numbers.”

Rohan Malhotra, Founder and CEO of Roadzen
4:29 PM ET 8-K
Financial Results SharonAI Holdings Inc. SHAZ

SharonAI Holdings Financial Results

Roadzen reported record revenue of $17.6 million for the second fiscal quarter, up 28.6% year-over-year, and achieved its first positive Adjusted EBITDA quarter in company history. The company also announced a $10 million equity financing for its India subsidiary at a $300 million post-money valuation and reaffirmed its target to exit fiscal 2027 at a $100 million-plus annualized revenue run rate.

Term
Q2 2027

“This is the quarter we have been building toward for two years. Roadzen generated positive Adjusted EBITDA for the first time in its history, on record revenue of $17.6 million, our third record quarter in a row, after nine consecutive quarters of disciplined improvement.”

Rohan Malhotra, Founder and CEO of Roadzen

“We process more than three million claims a year, our driver-safety AI runs across billions of miles of real-world driving, and our AI agents now do work inside inspection, claims and repair that used to take weeks, and that is the engine behind these numbers.”

Rohan Malhotra, Founder and CEO of Roadzen
4:29 PM ET 8-K
Financial Results Infleqtion, Inc. INFQ

Infleqtion Financial Results

Infleqtion reported record Q3 2026 revenue of $9.1 million, a 25% year-over-year increase, driven by its neutral atom quantum computing and sensing business. The company achieved a major technical milestone by demonstrating 30 logical qubits and maintained its full-year 2026 revenue guidance of at least $45.1 million.

Term
Q3 2026

“We are building Infleqtion to lead in utility-scale quantum computing, and this quarter’s progress strengthens our confidence in that ambition. Delivering 30 logical qubits is an important step on our technology roadmap. Alongside that progress, growth in our backlog and remaining performance obligations gives us confidence in a strong 2027 across computing and sensing, with computing becoming a meaningfully larger part of our business.”

Matt Kinsella, CEO of Infleqtion
4:29 PM ET 8-K
Investor Presentation agilon health, inc. AGL

agilon health Investor Presentation

agilon health, inc. is hosting a virtual investor event on November 17, 2026, to present its strategic framework for driving performance at scale. The company filed a formal investor presentation deck as an exhibit, which includes discussions on its technology-enabled clinical programs and long-term growth trajectory.

4:29 PM ET 8-K
Financial Results Aecom ACM

Aecom Financial Results

AECOM reported fourth quarter and full year fiscal 2026 results, achieving record wins and a 13% backlog growth to an all-time high of $28.0 billion. The company also announced a 10% increase in its quarterly cash dividend to $0.34 per share and initiated fiscal 2027 guidance reflecting strong growth expectations.

Term
FY2026

“Our full year performance, including record wins, backlog and fourth quarter margins, strengthen our confidence that our strategy and investments are delivering results.”

Troy Rudd, AECOM’s chairman and chief executive officer

“Our underlying cash flow was very strong, resulting in full year free cash flow that was ahead of our prior guidance.”

Gaurav Kapoor, AECOM’s chief financial and operations officer
4:29 PM ET 8-K
Financial Results Stem, Inc. STEM

Stem Financial Results

Stem, Inc. reported Q3 2026 financial results, highlighting a shift in strategy to focus on its high-margin PowerTrack software while de-emphasizing Managed Services and battery hardware resale. The company achieved record solar assets under management of 40 GW and reported positive adjusted EBITDA of $7.1 million, though it lowered full-year revenue and ARR guidance due to the strategic pivot.

Term
Q3 2026

“Our third quarter shows the operating leverage of a business built around PowerTrack. PowerTrack software revenue grew 18% year-over-year, we achieved a record 40 gigawatts of solar assets under management, and we were selected for the first utility-scale solar project in the Republic of Georgia.”

Arun Narayanan, Chief Executive Officer of Stem

“We delivered another quarter of strong margins and adjusted EBITDA, with non-GAAP gross margin of 58% and adjusted EBITDA of $7.1 million, more than triple the third quarter of 2025.”

Brian Musfeldt, Chief Financial Officer of Stem
4:29 PM ET 8-K
Shareholder Meeting Valion Bio, Inc. VBIO

Valion Bio Shareholder Meeting

Valion Bio held a special meeting of stockholders on November 12, 2026, where shareholders approved three key proposals. These included granting the board discretionary authority to effect a reverse stock split (ratio between 1-for-2 and 1-for-12) and amending the 2021 Equity Incentive Plan to increase the authorized share reserve by 272,000 shares.

4:29 PM ET Form 4
Insider Selling Richardson Electronics, Ltd. RELL

Richardson Electronics COO Wendy Diddell Sells $140K of Stock

Wendy Diddell, COO, sold 6,993 shares of Richardson Electronics, Ltd. at $20.03 a share, worth $140K in total on Nov 12, 2026. Shares held after the trade: 107,157 (-6.1%).

Value
$140K
Shares
6,993
Price
$20.03
Role
COO
Holding change
-6.1%
Trade date
Nov 12, 2026
4:29 PM ET Form 4
Insider Buying Amdocs Ltd DOX

Amdocs Director Adrian Gardner Buys $215K of Stock

Adrian Gardner, Director, bought 5,000 shares of Amdocs Ltd at $43.02 a share, worth $215K in total on Nov 12, 2026. Shares held after the trade: 25,000 (+25.0%).

Value
$215K
Shares
5,000
Price
$43.02
Role
Director
Holding change
+25.0%
Trade date
Nov 12, 2026
4:29 PM ET 8-K
Nasdaq/NYSE Compliance Notice Connect Biopharma Holdings Ltd CNTB

Connect Biopharma Holdings Nasdaq/NYSE Compliance Notice

Connect Biopharma received a deficiency notice from Nasdaq on November 12, 2026, because its ordinary shares closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until May 11, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for at least ten consecutive business days. The notice has no immediate effect on the listing of the company's shares, which continue to trade under the symbol 'CNTB'.

Counterparty
Nasdaq
Term
180 days

“We believe topline results from our Phase 2 Seabreeze STAT asthma and COPD studies mark a significant inflection point in the development of rademikibart as an add-on treatment to rescue bronchodilators and systemic corticosteroids for the treatment of acute exacerbations.”

Barry Quart, Pharm.D., CEO and Director of Connect Biopharma

“We believe these findings support the potential of rademikibart to redefine how acute exacerbations are managed, addressing both the acute event and the 4-week high-risk period following an exacerbation, to improve patient outcomes and reduce the substantial economic burden on healthcare systems.”

Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
4:29 PM ET 8-K
Clinical Trial Data CervoMed Inc. CRVO

CervoMed Clinical Trial Data

CervoMed presented 24-week interim biomarker data from its Phase 2a trial of neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA). The data showed an exposure-dependent reduction in neurofilament light chain (NfL), a key biomarker of neuronal damage, in patients with higher plasma drug levels. Full 24-week biomarker and clinical data from the study are expected in the first quarter of 2027.

Term
24 weeks
4:28 PM ET 8-K
M&A Deal Rapid Micro Biosystems, Inc. RPID

Rapid Micro Biosystems M&A Deal with Merck KGaA, Darmstadt, Germany

Rapid Micro Biosystems has entered into a definitive merger agreement to be acquired by Merck KGaA, Darmstadt, Germany for $0.75 per share in an all-cash tender offer. Following the transaction, which is expected to close in December 2026, Rapid Micro Biosystems will become a wholly owned subsidiary of Merck KGaA's Life Science business. The deal aims to expand the reach of the Growth Direct platform for automated microbial quality control in pharmaceutical manufacturing.

Counterparty
Merck KGaA, Darmstadt, Germany
4:28 PM ET 8-K
Financial Results Brainstorm Cell Therapeutics Inc. BCLI

Brainstorm Cell Therapeutics Financial Results

BrainStorm Cell Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a corporate update on its Phase 3b ENDURANCE study of NurOwn in ALS. The company highlighted the appointment of former FDA official Professor Peter J. Pitts as Executive Chairman to lead regulatory and capital-markets initiatives. Net loss for the quarter was $2.1 million, or $0.03 per share, as the company prepares for the initiation of its next clinical trial phase.

Term
Q3 2026

“ALS remains a devastating disease with a critical unmet medical need, and patients urgently need new therapeutic options. We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn® in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment.”

Chaim Lebovits, President and Chief Executive Officer
4:28 PM ET 8-K
Financial Results Aqua Metals, Inc. AQMS

Aqua Metals Financial Results

Aqua Metals reported third quarter 2026 financial results, highlighting a 19% year-over-year reduction in operating expenses. The company established offtake pathways via letters of intent for all three primary product streams at its Project Headwaters ARC facility, including copper, aluminum, and lithium carbonate.

“The third quarter was about converting commercial discussions into agreements and lowering the cost of carrying the business while we advance the funding strategy for Project Headwaters ARC.”

Steve Cotton, President and Chief Executive Officer

“We end the quarter with offtake pathways across all three primary product streams, a better-defined Phase 1 project and a lower cost base. Each of those puts Aqua Metals in a better position to act as funding and policy conditions become clearer.”

Steve Cotton, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.